{"id":"NCT04711902","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.","officialTitle":"A Phase III Randomized, Double-blind, Placebo Controlled, Multicenter, Bridging Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Sixteen Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy Follow-up to One Year in Chinese Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-24","primaryCompletion":"2022-06-02","completion":"2023-03-10","firstPosted":"2021-01-15","resultsPosted":"2024-07-19","lastUpdate":"2024-10-09"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"AIN457","otherNames":["Secukinumab"]},{"type":"OTHER","name":"Secukinumab Placebo","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"PLACEBO_COMPARATOR"},{"label":"Arm 3","type":"ACTIVE_COMPARATOR"},{"label":"Arm 4","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.","primaryOutcome":{"measure":"ACR20 Response at Week 16","timeFrame":"16 weeks","effectByArm":[{"arm":"Secukinumab 150 mg (Group 1)","deltaMin":14,"sd":null},{"arm":"Placebo of Study Drug (Group 2)","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2170"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Hyperlipidaemia","Hyperuricaemia","COVID-19","Hepatic function abnormal","Suspected COVID-19"]}}